The end of a dogma: the safety of doxycycline use in young children for malaria treatment

Tiphaine Gaillard (1, 2) , Sebastien Briolant (3) , Marylin Madamet (3) , Bruno Pradines (3)

1 Fédération des Laboratoires
2 Unité de Parasitologie
3 URMITE - Unité de Recherche sur les Maladies Infectieuses Tropicales Emergentes

Anti-malarial drug resistance to chloroquine and sulfadoxine-pyrimethamine has spread from Southeast Asia to Africa. Furthermore, the recent emergence of resistance to artemisinin-based combination therapy (ACT) in South-east Asia highlights the need to identify new anti-malarial drugs. Doxycycline is recommended for malaria chemoprophylaxis for travel in endemic areas, or in combination with the use of quinine for malaria treatment when ACT is unavailable or when the treatment of severe malaria with artesunate fails. However, doxycycline is not used in young children under 8 years of age due to its contraindication due to the risk of yellow tooth discolouration and dental enamel hypoplasia. Doxycycline was developed after tetracycline and was labelled with the same side-effects as the earlier tetracyclines. However, recent studies report little or no effects of doxycycline on tooth staining or dental enamel hypoplasia in children under 8 years of age. In the United States, the Centers for Disease Control and Prevention have recommended the use of doxycycline for the treatment of acute and chronic Q fever and tick-borne rickettsial diseases in young children. It is time to rehabilitate doxycycline and to recommend it for malaria treatment in children under 8 years of age.

Domaines: Maladies infectieuses

Tiphaine Gaillard, Sebastien Briolant, Marylin Madamet, Bruno Pradines. The end of a dogma: the safety of doxycycline use in young children for malaria treatment. Malaria Journal, 2017, 16 (1), ⟨10.1186/s12936-017-1797-9⟩. ⟨hal-01573776⟩